A Phase 3 interventional study of Maraviroc and Emtricitabine/tenofovir in HIV-1, sponsored by ViiV Healthcare. Terminated at 177 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.
The study was terminated on October 8, 2013 following a preliminary review of the Week 48 primary efficacy data by the study's external independent Data Monitoring Committee (DMC). The DMC assessed the data as demonstrating significant differences between the treatment arms in virologic responses and failures. The DMC recommended and the Sponsor concurred that the study be terminated because of the inferior efficacy of the Maraviroc arm as compared to the comparator arm (Emtricitabine/Tenofovir).
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 813 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
Drug: Maraviroc · Drug: darunavir/ritonavir 800/100 mg · Drug: placebo for maraviroc
Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
Drug: Emtricitabine/tenofovir · Drug: placebo for emtricitabine/tenofovir
Maraviroc tablet 150 mg once daily for 96 weeks.
Also known as: Selzentry, Celsentri
Drug pages: Emtricitabine · Tenofovir
Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
Also known as: Truvada
darunavir/ritonavir 800/100 mg
placebo for emtricitabine/tenofovir
Also known as: Truvada
placebo for maraviroc
Also known as: Selzentry, Celsentri
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
The proportion of participants who achieved HIV-1 RNA \<50 copies/mL at week 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm used the plasma HIV-1 RNA in the Week 48 visit window, followed the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
Time frame: Week 48
Frequency of Adverse Events (AE).
Number of participants with treatment-emergent non serious AEs
Time frame: Week 96
Number of Participants With Grade 3 or 4 AEs
Number of participants with grade 3 or 4 AEs are presented here.
Time frame: Week 96
Number of Participants Who Discontinued Due to AEs
Number of participants who discontinued due to AEs are reported here. Three participants (two from the MVC+DRV/r arm and one from the FTC/TDF+DRV/r arm) were not considered as discontinued due to AE because other reasons for discontinuation were prioritized for these participants.
Time frame: Week 96
Number of Treatment-related AEs
Number of treatment-related AEs are presented here.
Time frame: Week 96
Number of Participants With Treatment-emergent Serious Adverse Events
Total number of participants with treatment-emergent serious adverse events are reported
Time frame: Week 96
Number of Participants With Abnormal Laboratory Values
Number of participants with laboratory abnormalities are reported
Time frame: Week 96
Severity of Abnormal Laboratory Values
Number of participants who had clinically significant laboratory abnormalities of Grade 3 and Grade 4 according to DAIDS. Abnormality incidence of highest grade was reported for a labcode for each individual participant.
Time frame: Week 96
The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
The relationship of the proportion of participants achieving HIV-1 RNA \<50 copies/mL at Week 48 with the screening tropism test for the MVC containing regimen was analyzed. Virologic response for a participant at Week 48 was derived using the FDA's Snapshot MSDF algorithm. Difference in proportions of patients with plasma HIV-1 RNA \<50 copies/mL at week 48 between the maraviroc and the emtricitabine/tenofovir treatment arms, with two-sided 95% confidence interval, among patients who are R5 by genotype (including some who were originally randomized to ESTA and are R5 by genotype upon retesting), were calculated via the Maximum Likelihood method. The estimate was adjusted for the screening plasma HIV RNA level (\<100,000 vs. ≥100,000) copies/mL via the Mantel Haenszel (MH) method.
Time frame: Week 48
Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
Per the protocol participants who meet the following criteria were regarded as PDTFs requiring a confirmatory plasma HIV-1 RNA determination: • Decrease in plasma HIV-1 RNA \<1 log10 from baseline after Week 4 unless plasma HIV-1 RNA is \<50 copies/mL, or • Plasma HIV-1 RNA \>1.0 log10 above the nadir value after Week 4 where the nadir is the lowest plasma HIV-1 RNA concentration, or • Plasma HIV-1 RNA ≥50 copies/mL at any time after Week 24, or • Plasma HIV-1 RNA ≥50 copies/mL after suppression to \<50 copies/mL on two consecutive visits, or • Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<400 copies/mL. Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<50 copies/mL (before August 30 2012) or \<400 copies/mL (after August 30 2012).
Time frame: Week 48
Tropism Change Between Screening or Baseline and PDTF
For participants meeting the PDTF criteria, tropism was assessed using the original randomized and alternate assays (ie, both genotype testing and ESTA). Data reported here corresponds to the timepoint at or after PDTF.
Time frame: Week 48
Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
For participants meeting the PDTF criteria, viral resistance to maraviroc for maraviroc treated participants was assessed in patients with R5 virus at failure. The resistance level is calculated by reference to a laboratory strain of virus that is analyzed in parallel with the clinical isolate to identify 50% inhibitory concentrations (IC50). The maximal percent inhibition is the percent inhibition that is achieved in a titration of the drug at high concentrations when the addition of more drug does not result in increased inhibition. Maximal percent inhibition is obtained in the same way as the titration for IC50, but the key measure is of the plateau height of percent inhibition, where increased concentration of maraviroc does not result in additional inhibition. This is consistent with the virus developing some ability to use maraviroc-bound CCR5 for entry. A significant change in IC50 is not required for this mechanism.
Time frame: Week 48
Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
For participants meeting the PDTF criteria, viral resistance (both genotypic and phenotypic) to NRTI, NNRTI, and PI's were assessed at Baseline and on-treatment. The assessment was performed using the overall (i.e. net) susceptibility score provided using the PhenoSense GT assay. The number of participants with successful assessments were 15/17 for the MVC+DRV/r arm and 3/3 for the FTC/TDF+DRV/r arm.
Time frame: Week 48
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
The differences in the magnitude of changes in CD4+ at Baseline and at Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Time frame: Baseline, Week 48
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
The differences in the magnitude of changes in CD4+ from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Time frame: Baseline, Week 48
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
The differences in the magnitude of changes in CD8+ cell counts from baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Time frame: Baseline, Week 48
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
The differences in the magnitude of changes in CD8+ cell counts from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Time frame: Baseline, Week 48
Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
The differences in the magnitude of changes in CD4+/CD8+ ratio from Baseline through Weeks 48 for maraviroc versus emtricitabine/tenofovir were compared.
Time frame: Baseline, Week 48
Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
Time frame: Week 48
Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
Time frame: Week 48
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4), left total hip and femoral neck as measured by the DEXA scan.
Time frame: Week 48
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from Baseline bone mineral density femoral neck as measured by the DEXA scan.
Time frame: Week 48
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4) as measured by the DEXA scan.
Time frame: Week 48
Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
Bone turnover marker, osteocalcin, was collected in the subset of participants participating in the DEXA scan sub-study.
Time frame: Week 48
Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
Bone turnover marker, C-telopeptide of type 1 collagen (CTx), was collected in the subset of participants participating in the DEXA scan sub-study.
Time frame: Week 48
Overall, 1423 participants were screened and 813 participants randomized in the study. A total of 797 participants were treated (396 were treated in the maraviroc + darunavir/ritonavir \[MVC+DRV/r\] group and 401 in the emtricitabine/tenofovir + darunavir/ritonavir \[FTC/TDF+DRV/r\] group). The study was conducted in 138 sites in 18 countries.
| Milestone | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Started | 396 | 401 |
| Completed | 35 | 42 |
| Not completed | 361 | 359 |
| Withdrew: Adverse event | 22 | 23 |
| Withdrew: Lost to follow-up | 17 | 16 |
| Withdrew: Protocol violation | 4 | 1 |
| Withdrew: Medication error without associated ae | 0 | 1 |
| Withdrew: Study terminated by sponsor | 254 | 285 |
| Withdrew: Other reasons | 6 | 8 |
| Withdrew: Withdrawn due to pregnancy | 1 | 2 |
| Withdrew: No longer willing to participate | 9 | 12 |
| Withdrew: Insufficient clinical response | 48 | 11 |
The proportion of participants who achieved HIV-1 RNA \<50 copies/mL at week 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm used the plasma HIV-1 RNA in the Week 48 visit window, followed the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
| Percentage of participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL. | 77.3 | 86.8 |
Number of participants with treatment-emergent non serious AEs
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Frequency of Adverse Events (AE). | 360 | 365 |
Number of participants with grade 3 or 4 AEs are presented here.
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Number of Participants With Grade 3 or 4 AEs | 65 | 71 |
Number of participants who discontinued due to AEs are reported here. Three participants (two from the MVC+DRV/r arm and one from the FTC/TDF+DRV/r arm) were not considered as discontinued due to AE because other reasons for discontinuation were prioritized for these participants.
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Number of Participants Who Discontinued Due to AEs | 22 | 23 |
Number of treatment-related AEs are presented here.
| events | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Number of Treatment-related AEs | 316 | 361 |
Total number of participants with treatment-emergent serious adverse events are reported
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events | 41 | 40 |
Number of participants with laboratory abnormalities are reported
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Normal Baseline | 210 | 205 |
| Abnormal Baseline | 111 | 101 |
Number of participants who had clinically significant laboratory abnormalities of Grade 3 and Grade 4 according to DAIDS. Abnormality incidence of highest grade was reported for a labcode for each individual participant.
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Alanine Aminotransferase (ALT) (n=396, 400) | 9 | 6 |
| Alkaline Phosphatase (n=396, 400) | 1 | 0 |
| Amylase (n=396, 400) | 5 | 13 |
| Aspartate Aminotransferase (AST) (n=396, 400) | 11 | 7 |
| Blood Urea Nitrogen (BUN) (n=396, 400) | 3 | 5 |
| Calcium (n=396, 400) | 7 | 10 |
| Creatine Kinase (n=396, 400) | 18 | 22 |
| Hemoglobin (n=396, 400) | 4 | 2 |
| LDL Cholesterol (n=396, 400) | 50 | 24 |
| Lipase (n=116, 122) | 3 | 10 |
| Lymphocytes (Abs) (n=396, 400) | 2 | 2 |
| Phosphate (n=396, 400) | 5 | 12 |
| Platelets (n=396, 400) | 5 | 1 |
| Potassium (n=396, 400) | 3 | 2 |
| Sodium (n=396, 400) | 2 | 0 |
| Total Bilirubin (n=396, 400) | 3 | 1 |
| Total Neutrophils (Abs) (n=396, 400) | 6 | 2 |
| Triglycerides (n=396, 400) | 4 | 6 |
| Uric Acid (n=396, 400) | 0 | 2 |
| White Blood Cell Count (n=396, 400) | 1 | 0 |
| Creatinine (n=396, 400) | 0 | 1 |
The relationship of the proportion of participants achieving HIV-1 RNA \<50 copies/mL at Week 48 with the screening tropism test for the MVC containing regimen was analyzed. Virologic response for a participant at Week 48 was derived using the FDA's Snapshot MSDF algorithm. Difference in proportions of patients with plasma HIV-1 RNA \<50 copies/mL at week 48 between the maraviroc and the emtricitabine/tenofovir treatment arms, with two-sided 95% confidence interval, among patients who are R5 by genotype (including some who were originally randomized to ESTA and are R5 by genotype upon retesting), were calculated via the Maximum Likelihood method. The estimate was adjusted for the screening plasma HIV RNA level (\<100,000 vs. ≥100,000) copies/mL via the Mantel Haenszel (MH) method.
| proportion of participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA). | 0.8047 ± 0.0238 | 0.8797 ± 0.0187 |
Per the protocol participants who meet the following criteria were regarded as PDTFs requiring a confirmatory plasma HIV-1 RNA determination: • Decrease in plasma HIV-1 RNA \<1 log10 from baseline after Week 4 unless plasma HIV-1 RNA is \<50 copies/mL, or • Plasma HIV-1 RNA \>1.0 log10 above the nadir value after Week 4 where the nadir is the lowest plasma HIV-1 RNA concentration, or • Plasma HIV-1 RNA ≥50 copies/mL at any time after Week 24, or • Plasma HIV-1 RNA ≥50 copies/mL after suppression to \<50 copies/mL on two consecutive visits, or • Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<400 copies/mL. Decrease in plasma HIV-1 RNA ≤2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is \<50 copies/mL (before August 30 2012) or \<400 copies/mL (after August 30 2012).
| Number of participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Confirmed PDTF | 40 | 13 |
| Evaluable PDTF | 17 | 3 |
For participants meeting the PDTF criteria, tropism was assessed using the original randomized and alternate assays (ie, both genotype testing and ESTA). Data reported here corresponds to the timepoint at or after PDTF.
| participants | MVC+DRV/r - Baseline | MVC+DRV/r - Failure | FTC/TDF+DRV/r - Baseline | FTC/TDF+DRV/r - Failure |
|---|---|---|---|---|
| R5 (Randomized Assay) | 14 | 13 | 2 | 1 |
| NON R5 (Randomized Assay) | 1 | 1 | 0 | 0 |
| NR (Randomized Assay) | 2 | 3 | 1 | 2 |
| R5 (Alternate Assay) | 10 | 10 | 3 | 2 |
| NON R5 (Alternate Assay) | 2 | 3 | 0 | 1 |
| NR (Alternate Assay) | 5 | 4 | 0 | 0 |
For participants meeting the PDTF criteria, viral resistance to maraviroc for maraviroc treated participants was assessed in patients with R5 virus at failure. The resistance level is calculated by reference to a laboratory strain of virus that is analyzed in parallel with the clinical isolate to identify 50% inhibitory concentrations (IC50). The maximal percent inhibition is the percent inhibition that is achieved in a titration of the drug at high concentrations when the addition of more drug does not result in increased inhibition. Maximal percent inhibition is obtained in the same way as the titration for IC50, but the key measure is of the plateau height of percent inhibition, where increased concentration of maraviroc does not result in additional inhibition. This is consistent with the virus developing some ability to use maraviroc-bound CCR5 for entry. A significant change in IC50 is not required for this mechanism.
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Not eligible for analysis (failed tropism test) | 4 | 1 |
| Not eligible for analysis (non-R5 tropism) | 1 | 1 |
| Eligible for analysis (R5 virus using ESTA) | 12 | 1 |
| Results reported | 12 | 1 |
| Maximal percent inhibition <95% | 0 | 0 |
| IC50 FC ≥3.0 | 0 | 0 |
For participants meeting the PDTF criteria, viral resistance (both genotypic and phenotypic) to NRTI, NNRTI, and PI's were assessed at Baseline and on-treatment. The assessment was performed using the overall (i.e. net) susceptibility score provided using the PhenoSense GT assay. The number of participants with successful assessments were 15/17 for the MVC+DRV/r arm and 3/3 for the FTC/TDF+DRV/r arm.
| participants | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| NRTI - All (Baseline, n=15, 3) | 0 | 0 |
| NNRTI Delavirdine (Baseline, n=15, 3) | 1 | 0 |
| NNRTI Nevirapine (Baseline, n=15, 3) | 1 | 0 |
| NNRTI Efavirenz (Baseline, n=15, 3) | 1 | 0 |
| PRI - All (Baseline, n=15, 3) | 0 | 0 |
| NRTI - All (PDTF, n=15, 3) | 0 | 0 |
| NNRTI Delavirdine (PDTF, n=15, 3) | 1 | 0 |
| NNRTI Nevirapine (PDTF, n=15, 3) | 1 | 0 |
| NNRTI Efavirenz (PDTF, n=15, 3) | 1 | 0 |
| PRI - All (PDTF, n=15, 3) | 0 | 0 |
The differences in the magnitude of changes in CD4+ at Baseline and at Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
| cell/mm^3 | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Baseline (n=396, 401) | 382.0 ± 173.4 | 379.5 ± 170.9 |
| Week 48 (n=394, 396) | 576.9 ± 226.0 | 574.6 ± 232.1 |
| Change from Baseline at Week 48 (n=394, 396) | 194.9 ± 175.5 | 194.2 ± 175.8 |
The differences in the magnitude of changes in CD4+ from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
| Percentage of lymphocytes | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Baseline (n=396, 401) | 24.2 ± 7.9 | 24.5 ± 8.2 |
| Week 48 (n=394, 396) | 31.3 ± 8.3 | 33.7 ± 8.6 |
| Change from Baseline at Week 48 (n=394, 396) | 7.0 ± 5.7 | 9.2 ± 6.0 |
The differences in the magnitude of changes in CD8+ cell counts from baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
| cell/mm^3 | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Baseline (n=396, 401) | 954.4 ± 502.1 | 914.5 ± 473.0 |
| Week 48 (n=394, 396) | 900.0 ± 508.3 | 751.1 ± 386.7 |
| Change from Baseline at Week 48 (n=394, 396) | -49.9 ± 410.7 | -157.9 ± 444.0 |
The differences in the magnitude of changes in CD8+ cell counts from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
| Percentage of lymphocytes | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Baseline (n=396, 401) | 57.0 ± 10.7 | 55.8 ± 10.5 |
| Week 48 (n=394, 396) | 46.0 ± 10.4 | 43.0 ± 10.2 |
| Change from Baseline at Week 48 (n=394, 396) | -10.9 ± 7.2 | -12.6 ± 8.1 |
The differences in the magnitude of changes in CD4+/CD8+ ratio from Baseline through Weeks 48 for maraviroc versus emtricitabine/tenofovir were compared.
| Ratio | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Baseline (n=396, 401) | 0.47 ± 0.24 | 0.48 ± 0.25 |
| Week 48 (n=394, 396) | 0.75 ± 0.34 | 0.87 ± 0.45 |
| Change from Baseline at Week 48 (n=394, 396) | 0.28 ± 0.22 | 0.39 ± 0.34 |
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
| gram | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48. | -181.6 ± 569.8 | -257.5 ± 556.9 |
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
| ratio | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48 | 0.017 ± 0.048 | -0.014 ± 0.048 |
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4), left total hip and femoral neck as measured by the DEXA scan.
| g/cm^2 | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD | -0.014 ± 0.005 | -0.028 ± 0.005 |
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from Baseline bone mineral density femoral neck as measured by the DEXA scan.
| g/cm^2 | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD | -0.021 ± 0.007 | -0.029 ± 0.007 |
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4) as measured by the DEXA scan.
| g/cm^2 | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD | -0.020 ± 0.006 | -0.025 ± 0.006 |
Bone turnover marker, osteocalcin, was collected in the subset of participants participating in the DEXA scan sub-study.
| ng/mL | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin | 5.61 ± 8.02 | 6.77 ± 8.31 |
Bone turnover marker, C-telopeptide of type 1 collagen (CTx), was collected in the subset of participants participating in the DEXA scan sub-study.
| pg/mL | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1) | 121.13 ± 243.03 | 223.52 ± 293.03 |
Collected over From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MVC+DRV/r | — | 41/396 (10.4%) | 257/396 (64.9%) |
| FTC/TDF+DRV/r | — | 40/401 (10%) | 285/401 (71.1%) |
| Event | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| ColitisGastrointestinal disorders | 2/396 | 0/401 |
| Chest painGeneral disorders | 2/396 | 1/401 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/396 | 0/401 |
| DepressionPsychiatric disorders | 2/396 | 1/401 |
| Acute hepatitis CInfections and infestations | 0/396 | 2/401 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/396 | 2/401 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/396 | 2/401 |
| Suicidal ideationPsychiatric disorders | 1/396 | 2/401 |
| Suicide attemptPsychiatric disorders | 1/396 | 2/401 |
| Drug rehabilitationSurgical and medical procedures | 0/396 | 2/401 |
| Event | MVC+DRV/r | FTC/TDF+DRV/r |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 88/396 | 135/401 |
| NasopharyngitisInfections and infestations | 48/396 | 55/401 |
| HeadacheNervous system disorders | 27/396 | 47/401 |
| FatigueGeneral disorders | 27/396 | 46/401 |
| NauseaGastrointestinal disorders | 34/396 | 45/401 |
| Upper respiratory tract infectionInfections and infestations | 40/396 | 45/401 |
| RashSkin and subcutaneous tissue disorders | 37/396 | 30/401 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/396 | 30/401 |
| DepressionPsychiatric disorders | 26/396 | 29/401 |
| BronchitisInfections and infestations | 25/396 | 24/401 |
| Age, Continuous(Years) | MVC+DRV/r | FTC/TDF+DRV/r | Total |
|---|---|---|---|
| Mean | 37.9 ± 10.9 | 36.2 ± 10.9 | 37.1 ± 10.9 |
| Sex: Female, Male(Participants) | MVC+DRV/r | FTC/TDF+DRV/r | Total |
|---|---|---|---|
| Female | 36 | 34 | 70 |
| Male | 360 | 367 | 727 |
Showing the first 100 of 177 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Aug 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc
Acquired Immunodeficiency Syndrome →